Table of Content

1 Neulasta (Pegfilgrastim) and Biosimilar Market Overview
1.1 Product Overview and Scope of Neulasta (Pegfilgrastim) and Biosimilar
1.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
1.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2024-2034)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
1.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue 2018-2034
1.4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales 2018-2034
1.4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Neulasta (Pegfilgrastim) and Biosimilar Market Competition by Manufacturers
2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Neulasta (Pegfilgrastim) and Biosimilar Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Product Type & Application
2.7 Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends
2.7.1 Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue
2.7.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neulasta (Pegfilgrastim) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2018-2034
3.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2024-2034
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018-2034
3.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2024-2034
3.4 North America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2034)
3.4.3 North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2034)
3.5.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2034)
3.6.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2034)
3.7.3 Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2034)
3.8.3 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2018-2034)
4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2024-2034)
4.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2018-2034)
4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2018-2034)
4.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2024-2034)
4.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2018-2034)
4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2018-2034)
5 Segment by Application
5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2018-2034)
5.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2024-2034)
5.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2018-2034)
5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2018-2034)
5.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2024-2034)
5.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2018-2034)
5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Viatris
6.2.1 Viatris Corporation Information
6.2.2 Viatris Description and Business Overview
6.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.2.5 Viatris Recent Developments/Updates
6.3 Coherus
6.3.1 Coherus Corporation Information
6.3.2 Coherus Description and Business Overview
6.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.3.5 Coherus Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Amneal Pharmaceutical
6.6.1 Amneal Pharmaceutical Corporation Information
6.6.2 Amneal Pharmaceutical Description and Business Overview
6.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.6.5 Amneal Pharmaceutical Recent Developments/Updates
6.7 Fresenius Kabi
6.6.1 Fresenius Kabi Corporation Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.7.5 Fresenius Kabi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis
7.2 Neulasta (Pegfilgrastim) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neulasta (Pegfilgrastim) and Biosimilar Production Mode & Process
7.4 Neulasta (Pegfilgrastim) and Biosimilar Sales and Marketing
7.4.1 Neulasta (Pegfilgrastim) and Biosimilar Sales Channels
7.4.2 Neulasta (Pegfilgrastim) and Biosimilar Distributors
7.5 Neulasta (Pegfilgrastim) and Biosimilar Customers
8 Neulasta (Pegfilgrastim) and Biosimilar Market Dynamics
8.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Trends
8.2 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
8.3 Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
8.4 Neulasta (Pegfilgrastim) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation by Manufacturers in 2024
Table 4. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Neulasta (Pegfilgrastim) and Biosimilar, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Product Type & Application
Table 12. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neulasta (Pegfilgrastim) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neulasta (Pegfilgrastim) and Biosimilar as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2018-2023) & (K Units)
Table 18. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2018-2023)
Table 19. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2024-2034) & (K Units)
Table 20. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2024-2034)
Table 21. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2018-2023)
Table 23. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2024-2034)
Table 25. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)
Table 27. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2034) & (K Units)
Table 28. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)
Table 32. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2034) & (K Units)
Table 33. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Type (2018-2023)
Table 51. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Type (2024-2034)
Table 52. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2018-2023)
Table 53. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2024-2034)
Table 54. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2018-2023)
Table 57. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2024-2034)
Table 58. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2018-2023)
Table 59. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2024-2034)
Table 60. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Application (2018-2023)
Table 61. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Application (2024-2034)
Table 62. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2018-2023)
Table 63. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2024-2034)
Table 64. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2018-2023)
Table 67. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2024-2034)
Table 68. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2018-2023)
Table 69. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2024-2034)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product
Table 74. Amgen Recent Developments/Updates
Table 75. Viatris Corporation Information
Table 76. Viatris Description and Business Overview
Table 77. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product
Table 79. Viatris Recent Developments/Updates
Table 80. Coherus Corporation Information
Table 81. Coherus Description and Business Overview
Table 82. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product
Table 84. Coherus Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product
Table 89. Novartis Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Amneal Pharmaceutical Corporation Information
Table 96. Amneal Pharmaceutical Description and Business Overview
Table 97. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product
Table 99. Amneal Pharmaceutical Recent Developments/Updates
Table 100. Fresenius Kabi Corporation Information
Table 101. Fresenius Kabi Description and Business Overview
Table 102. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product
Table 104. Fresenius Kabi Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Neulasta (Pegfilgrastim) and Biosimilar Distributors List
Table 108. Neulasta (Pegfilgrastim) and Biosimilar Customers List
Table 109. Neulasta (Pegfilgrastim) and Biosimilar Market Trends
Table 110. Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
Table 111. Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
Table 112. Neulasta (Pegfilgrastim) and Biosimilar Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neulasta (Pegfilgrastim) and Biosimilar
Figure 2. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type in 2024 & 2034
Figure 4. Brand Product Picture
Figure 5. Biosimilar Product Picture
Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application in 2024 & 2034
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (2018-2034) & (US$ Million)
Figure 13. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (2018-2034) & (K Units)
Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price (US$/Unit) & (2018-2034)
Figure 15. Neulasta (Pegfilgrastim) and Biosimilar Report Years Considered
Figure 16. Neulasta (Pegfilgrastim) and Biosimilar Sales Share by Manufacturers in 2024
Figure 17. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers in 2024
Figure 18. The Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players: Market Share by Revenue in 2024
Figure 19. Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 21. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2034)
Figure 22. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2034)
Figure 23. United States Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 24. Canada Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 25. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2034)
Figure 26. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2034)
Figure 27. Germany Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 28. France Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. U.K. Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. Italy Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Russia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2018-2034)
Figure 33. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2018-2034)
Figure 34. China Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. Japan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. South Korea Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. India Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. Australia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. China Taiwan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2034)
Figure 42. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2034)
Figure 43. Mexico Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Brazil Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Argentina Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2034)
Figure 47. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2034)
Figure 48. Turkey Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. UAE Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Global Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2018-2034)
Figure 52. Global Revenue Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2018-2034)
Figure 53. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2018-2034)
Figure 54. Global Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Application (2018-2034)
Figure 55. Global Revenue Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Application (2018-2034)
Figure 56. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2018-2034)
Figure 57. Neulasta (Pegfilgrastim) and Biosimilar Value Chain
Figure 58. Neulasta (Pegfilgrastim) and Biosimilar Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed